tLNP CAR-T

tLNP CAR-T is an investigational therapeutic program being developed by TLC BioSciences (Taiwan Liposome Company) that combines Chimeric Antigen Receptor T-cell (CAR-T) technology with a proprietary targeted lipid nanoparticle (tLNP) delivery system. The program is positioned within the company's pipeline for the treatment of metabolic and immune disorders. The tLNP platform is designed for the targeted delivery of nucleic acids, suggesting that this program may involve the use of LNPs to deliver mRNA encoding a CAR to T cells, potentially allowing for *in vivo* CAR-T cell generation or the enhancement of *ex vivo* engineered cells. By utilizing targeted lipid nanoparticles, TLC BioSciences aims to overcome traditional delivery challenges and expand the application of CAR-T therapies beyond oncology into immunological and metabolic indications.